Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

June 15, 2025

Study Completion Date

July 1, 2025

Conditions

Lactation Suppressed

Interventions

DRUG

Cabergoline 1 MG

Dopamine agonist

DRUG

Placebo

Trial Locations (2)

Stanford University, Stanford

Planned Parenthood - San Jose Central Health Center, San Jose

All Listed Sponsors

collaborator

Planned Parenthood Mar Monte

UNKNOWN

lead

Stanford University

OTHER

NCT06029673 - Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss | Biotech Hunter | Biotech Hunter